拉米夫定单用与联用乙肝免疫球蛋白预防肝移植术后乙肝病毒复发Meta分析  

Comparative Meta-analysis of Efficacy of LAM Monotherapy verus LAM Combined HBIg in Preventing the Recurrence of Hepatitis B Virus after Liver Transplantion

作　　者：陈安进[1] 石杰[1] 张芳[1] 辛永宁[1] 

机构地区：[1]青岛市市立医院,山东青岛266011

出　　处：《药物流行病学杂志》2008年第3期147-150,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:应用Meta分析的方法评价拉米夫定(LAM)单用与联用乙肝免疫球蛋白(HBIg)预防肝移植术后乙肝病毒复发的疗效。方法:通过电子检索和手工检索,按照Cochrane协作网的系统评价员手册完成Meta分析。结果:共有13篇文献入选,均为病例对照研究。试验组肝移植术后乙肝病毒未复发率93.9%(766/816),对照组71.6%(140/197)。因入选文献不存在异质性,故采用固定效应模型,OR值为5.31(95% CI,3.23-8.73)。结论:HBIg与LAM合用可以有效地预防肝移植术后HBV再感染,其疗效优于单用LAM。Objective： To perform a comparative meta-analysis of efficacy of LAM monotherapy verus HBIg combined LAM in preventing the recurrence of hepatitis B virus in patients who had liver transplant. Method： A total of 102 clinical trials and reports were identified and only 13 trials were qualified for our selection criteria. Discrepancies in the evaluation of some of the studies were resolved through discussions between the reviewers. The meta-analysis was carried out by a biostatistician according to the Cochrane Reviewers＇Handbook recommended by The Cochrane Collaboration. Result： 13 studies were identified and reviewed. Therefore, 13 case-control studies were included in the final analysis. The non-recurrent rates were 93.9% （766 of 816） in the treatment group but 71.6% （ 140 of 197 ） in the controlled group. A summary OR （using the fixed-effects model, which accounted for no heterogeneity across the 13 studies） was found to be 5.31 （95% CI, 3, 23 -8.73 ）. Conclusion： The HBIG combined lamivudine demonstrates a better result than the lamivudine monotherapy in prophylaxis against HBV recurrence of post-LT.

关 键 词：拉米夫定 乙肝免疫球蛋白 肝移植 META分析 

分 类 号：R512.62[医药卫生—内科学]